The Diabetic Association of Bangladesh (BADAS), in association with Swedish insulin giant Novo Nordisk, will register a nationwide electronic diabetes patient list.
The electronic registry will be introduced in Bangladesh, the first of its kinds, with a view to delivering quality care for patient living with diabetes through analysing epidemiology and treatment outcomes.
Diabetic Association of Bangladesh’s (BADAS) President Prof AK Azad Khan and Novo Nordisk’s Senior Vice President Frederik Kier signed an agreement on Sunday to develop the registry system, says a press release Monday.
Prof Azad Khan said, “In Bangladesh there is no conclusive study or survey which provides an exact number or figure of the diabetic population.”
“The new nationwide registry will generate data on patient numbers, blood glucose level before and after meal, three-month average of glucose in blood (HbA1c), renal and cardiac history of patients living with diabetes and other relevance. Quality care will be ensured though analysing these data,” He said.
Frederick Kier said, “The new nationwide registry will provide health outcome data to monitor patient needs and identify health problems that need prompt attention. It will also help to address the rising burden of diabetes to achieve sustainable development goals (SDGs).”
The United Nations has recognised diabetes among other non-communicable diseases as a major challenge for achieving SDGs.
According to International Diabetes Federation, 6.9 million people are living with diabetes in Bangladesh and it will hit 13.7 million by 2045.
